---
title: "BioNexus advances VitaGuard Southeast Asia rollout after China hospital visits"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294070529.md"
description: "BioNexus advanced the Southeast Asia rollout of its VitaGuard MRD platform following working visits to Tongshu Gene facilities in Shanghai and Changzhou. Site visits to Chinese hospitals utilizing VitaGuard commercially support BioNexus's target for initial deployment in 2026."
datetime: "2026-07-28T13:00:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294070529.md)
  - [en](https://longbridge.com/en/news/294070529.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294070529.md)
generator: "portal-rs"
---

# BioNexus advances VitaGuard Southeast Asia rollout after China hospital visits

-   BioNexus attended a working visit to Tongshu Gene facilities in Shanghai and Changzhou to advance the VitaGuard MRD platform rollout in Southeast Asia. \* Sessions mapped implementation needs, with site visits to Chinese hospitals using VitaGuard commercially supporting BioNexus’s 2026 initial deployment target. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607280900PRIMZONEFULLFEED9799214) on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BGLC.US](https://longbridge.com/en/quote/BGLC.US.md)

## Related News & Research

- [Novogenia launches MGT Plus methylation genetic test in US market](https://longbridge.com/en/news/296876844.md)
- [CoreWeave Just Landed a Multibillion-Dollar AI Deal. How to Play CRWV Stock.](https://longbridge.com/en/news/296937988.md)
- [Imunon to host R&D day spotlighting Phase 3 OVATION 3 trial for IMNN-001 in ovarian cancer](https://longbridge.com/en/news/297045598.md)
- [Burning Rock CanCatch Custom MRD kit enters NMPA innovative device special review procedure](https://longbridge.com/en/news/296933190.md)
- [Adaptive Biotechnologies (ADPT), Why Is It Getting Fresh Attention Now?](https://longbridge.com/en/news/297264786.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**